Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 5c, provides guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.33 -1.84%
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +24.1%
Financial Fact:
Product sales: 38.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $50.5 million versus the consensus estimate of $52.4 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2024 revenue of $180-210 million, versus the consensus of $220.2 million.
Year-end 2024 Cash: $360 to $390 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts Carter's (CRI) at Outperform
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
